Immuneering Corp Total Assets
Immuneering Corp total assets. Based on the latest financial reports, Immuneering Corp (IMRX) holds total assets worth $241.06 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Immuneering Corp (IMRX) total market value for the company's overall valuation and market capitalisation.
Total Assets of Immuneering Corp (2019–2024)
Total assets of Immuneering Corp from 2019 to 2024. This chart illustrates how Immuneering Corp's total assets have evolved over time, based on quarterly financial data. See Immuneering Corp (IMRX) share price today for real-time trading data and today's change.
Immuneering Corp - Asset Composition Analysis
Immuneering Corp Total Assets Breakdown (December 2024)
Immuneering Corp total assets breakdown as of December 2024. Immuneering Corp's total assets of $241.06 Million consist of 75.1% current assets and 24.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 68.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $350.41K | 0.7% |
| Goodwill | $6.69 Million | 12.7% |
Asset Composition Trend (2019–2024)
This chart illustrates how Immuneering Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore IMRX working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Immuneering Corp's current assets represent 75.1% of total assets in 2024, a decrease from 99.8% in 2019.
- Cash Position: Cash and equivalents constituted 68.6% of total assets in 2024, down from 97.8% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 12.0% of total assets, an increase from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 12.7% of total assets.
Immuneering Corp Competitors by Total Assets
Key competitors of Immuneering Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Immuneering Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 24.00 | 7.99 | 16.73 |
| Quick Ratio | 24.00 | 7.99 | 16.73 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $219.56 Million | $48.34 Million | $35.48 Million |
Immuneering Corp - Advanced Valuation Insights
This section examines the relationship between Immuneering Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.40 |
| Latest Market Cap to Assets Ratio | 4.61 |
| Asset Growth Rate (YoY) | -48.6% |
| Total Assets | $52.71 Million |
| Market Capitalization | $242.78 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Immuneering Corp's assets at a significant premium (4.61x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Immuneering Corp's assets decreased by 48.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Immuneering Corp (2019–2024)
The table below shows the annual total assets of Immuneering Corp from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $52.71 Million | -48.61% |
| 2023-12-31 | $102.58 Million | -16.17% |
| 2022-12-31 | $122.37 Million | -26.60% |
| 2021-12-31 | $166.70 Million | +333.87% |
| 2020-12-31 | $38.42 Million | +172.53% |
| 2019-12-31 | $14.10 Million | -- |
About Immuneering Corp
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 … Read more